Clinical trial

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

NCT01591122

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-03-27

PhasePHASE3

Study timeline

Study start (actual)2012-03-27Date precision: day

Registry last updated2020-01-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

Placebo and prednisoneDRUG

Abiraterone acetate and prednisoneDRUG

Sponsors & collaborators

Janssen Research & Development, LLClead sponsor

Mapped research locations

MoscowRussia1 BeijingChina1 Saint PetersburgRussia1 ShanghaiChina1 BangkokThailand1 GuangzhouChina1 TianjinChina1 ChengduChina1 HangzhouChina1 NanjingChina1 WuhanChina1 Kuala LumpurMalaysia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01591122 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.